The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | FOLFIRINOX, gemcitabine + paclitaxel to enhance surgery outcomes for locally advanced PC
Combined chemotherapy with FOLFIRINOX, gemcitabine and paclitaxel has previously been demonstrated to improve overall-survival (OS) in metastatic pancreatic cancer. Rainer Fietkau, MD, PhD, University Hospital Erlangen, Erlangen, Germany discusses utilizing this chemotherapy regimen to help avoid the development of distant metastases in patients with locally advanced disease during induction chemotherapy to enhance the benefit of surgery. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
